<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330017</url>
  </required_header>
  <id_info>
    <org_study_id>18123</org_study_id>
    <secondary_id>CL2010-06</secondary_id>
    <secondary_id>P08156</secondary_id>
    <nct_id>NCT01330017</nct_id>
  </id_info>
  <brief_title>Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)</brief_title>
  <official_title>A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will evaluate the nasal congestion symptom relief of the approved 10 mg
      phenylephrine (PE) dose and the higher 20 mg, 30 mg, and 40 mg PE doses compared with placebo
      in participants with histories of seasonal allergic rhinitis, using loratadine as background
      medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. Participants rated congestion on a 4-point scale of severity from 0 (best) to 3 (worst), with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period. Baseline was defined as the average of the daily scores over the 4 consecutive 24-hour periods before randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</measure>
    <time_frame>Baseline and Days 2, 3, 4, 5, 6, and 7</time_frame>
    <description>The morning reflective nasal congestion score was captured in participant diaries just before the 8:00 am dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and it is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Evening (p.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</measure>
    <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
    <description>The evening reflective nasal congestion score was captured in participant diaries just before the 8;00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period</measure>
    <time_frame>Baseline and Day 2, 3, 4, 5, 6, and 7</time_frame>
    <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period</measure>
    <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
    <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period</measure>
    <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
    <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximal Effect</measure>
    <time_frame>Baseline up to Day 7</time_frame>
    <description>Time to maximal effect is defined as the earliest time that the nasal congestion symptom score demonstrates the greatest numerical difference from the placebo in change from baseline. The mean change from baseline scores for a treatment arm and for the placebo arm at each day and timepoint of the treatment period (Day 1 morn, Day 1 eve, etc) were calculated. Then the difference between the placebo and treatment arm means at each day/timepoint of the treatment period was calculated and recorded the day/timepoint that the difference between the treatment arm and the placebo was highest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>The magnitude of effect was measured as the change from baseline for the instantaneous nasal symptom assessment score at Day 7. Instantaneous assessment of nasal symptoms was performed once daily before the morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">539</enrollment>
  <condition>Rhinitis</condition>
  <condition>Seasonal Rhinitis</condition>
  <arm_group>
    <arm_group_label>PE 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PE 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PE 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PE 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine HCl</intervention_name>
    <description>10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days</description>
    <arm_group_label>PE 10 mg</arm_group_label>
    <arm_group_label>PE 20 mg</arm_group_label>
    <arm_group_label>PE 30 mg</arm_group_label>
    <arm_group_label>PE 40 mg</arm_group_label>
    <other_name>SCH 002063</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days</description>
    <arm_group_label>PE 10 mg</arm_group_label>
    <arm_group_label>PE 20 mg</arm_group_label>
    <arm_group_label>PE 30 mg</arm_group_label>
    <arm_group_label>PE 40 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.</description>
    <arm_group_label>PE 10 mg</arm_group_label>
    <arm_group_label>PE 20 mg</arm_group_label>
    <arm_group_label>PE 30 mg</arm_group_label>
    <arm_group_label>PE 40 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Claritin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female participants of reproductive potential must have a negative pregnancy test and
             agree to use acceptable methods of birth control throughout the study.

          -  Participant is willing to stop use of current decongestant and allergy medications
             during the trial.

          -  Participant has a documented or self-reported history of seasonal allergy.

          -  Participant has documented positive skin testing to spring pollen allergens.

          -  Participant has nasal congestion of at least moderate severity.

          -  Participant has mean seated (after 5 minutes of rest) systolic/diastolic blood
             pressure ≤138/88 mmHg.

          -  Participant has clinically acceptable physical exam and 12-lead electrocardiogram
             (ECG).

          -  Participant is without clinically significant disease.

          -  Participant must agree not to take monoamine oxidase inhibitor (MAOI) from 14 days
             before trial participation until 14 days after the end of the trial.

          -  Participant must sign an informed consent form

        Exclusion criteria:

          -  Participants must not have any significant medical condition that is a
             contraindication to the use of phenylephrine HCl or loratadine, such as thyroid
             disease, uncontrolled diabetes mellitus, coronary heart disease, ischemic heart
             disease, elevated intraocular pressure, or prostatic hypertrophy.

          -  Participants with a history or presence of hypertension.

          -  Participants who have started allergen immunotherapy within a month preceding
             enrollment or starting allergen immunotherapy or anticipating immunotherapy dose
             change during the trial. Xolair (omalizumab) may not be used within 4 years prior to
             trial participation.

          -  Participants who have a known allergy or intolerance to phenylephrine HCl, any other
             decongestant, loratadine, desloratadine, or any other antihistamine.

          -  Participants with persistent asthma, rhinitis medicamentosa, or acute or chronic
             sinusitis, or a history of significant sinusitis within one month of enrollment.

          -  Participant with a history of intermittent asthma may be considered for enrollment
             provided they have no asthma symptoms at the time of enrollment and use only a short
             acting beta2-agonist less than twice weekly.

          -  Participants who have used systemic (oral, rectal, injectable), topical, or nasal
             corticosteroids in the last 30 days (up to 1% topical hydrocortisone is permitted).

          -  Participants using a leukotriene receptor antagonist for maintenance treatment of
             asthma.

          -  Participant with a history of any illness that, in the opinion of the study
             investigator, might confound the results of the study or poses an additional risk to
             the participant by their participation in the study.

          -  Participant with a history of immunological disease or malignancy within the past 5
             years, with the exception of non-melanoma skin cancer.

          -  Participant with positive drug screen (participants on prescribed medication resulting
             in a positive drug screen result may still be enrolled at the discretion of the
             investigator).

          -  Participant has had major surgery or participated in another investigational study
             within 4 weeks prior to the Screening Visit.

          -  Participants taking any herbal supplements during trial conduct.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <results_first_submitted>May 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal allergies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PE 10 mg</title>
          <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="P2">
          <title>PE 20 mg</title>
          <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="P3">
          <title>PE 30 mg</title>
          <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="P4">
          <title>PE 40 mg</title>
          <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Matching placebo was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="112"/>
                <participants group_id="P5" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Reason</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PE 10 mg</title>
          <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="B2">
          <title>PE 20 mg</title>
          <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="B3">
          <title>PE 30 mg</title>
          <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="B4">
          <title>PE 40 mg</title>
          <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Matching placebo was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="112"/>
            <count group_id="B5" value="103"/>
            <count group_id="B6" value="539"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="11.25"/>
                    <measurement group_id="B2" value="36.8" spread="11.08"/>
                    <measurement group_id="B3" value="38.9" spread="12.65"/>
                    <measurement group_id="B4" value="39.6" spread="13.10"/>
                    <measurement group_id="B5" value="38.9" spread="11.96"/>
                    <measurement group_id="B6" value="38.7" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score</title>
        <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. Participants rated congestion on a 4-point scale of severity from 0 (best) to 3 (worst), with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period. Baseline was defined as the average of the daily scores over the 4 consecutive 24-hour periods before randomization.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>The Intent-to-Treat (ITT) population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score</title>
          <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. Participants rated congestion on a 4-point scale of severity from 0 (best) to 3 (worst), with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period. Baseline was defined as the average of the daily scores over the 4 consecutive 24-hour periods before randomization.</description>
          <population>The Intent-to-Treat (ITT) population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.460" spread="0.5374"/>
                    <measurement group_id="O2" value="-0.499" spread="0.5042"/>
                    <measurement group_id="O3" value="-0.508" spread="0.5618"/>
                    <measurement group_id="O4" value="-0.461" spread="0.5308"/>
                    <measurement group_id="O5" value="-0.428" spread="0.5530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4912</p_value>
            <p_value_desc>The p-value reflects mean change from baseline vs. placebo from an ANCOVA model with adjustments for baseline reflective score value, investigative site, age, and gender.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4519</p_value>
            <p_value_desc>The p-value reflects mean change from baseline vs. placebo from an ANCOVA model with adjustments for baseline reflective score value, investigative site, age, and gender.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2186</p_value>
            <p_value_desc>The p-value reflects mean change from baseline vs. placebo from an ANCOVA model with adjustments for baseline reflective score value, investigative site, age, and gender.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5983</p_value>
            <p_value_desc>The p-value reflects mean change from baseline vs. placebo from an ANCOVA model with adjustments for baseline reflective score value, investigative site, age, and gender.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</title>
        <description>The morning reflective nasal congestion score was captured in participant diaries just before the 8:00 am dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and it is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
        <time_frame>Baseline and Days 2, 3, 4, 5, 6, and 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Morning (a.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</title>
          <description>The morning reflective nasal congestion score was captured in participant diaries just before the 8:00 am dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and it is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 109, 108, 106, 111, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.417" spread="0.4327"/>
                    <measurement group_id="O2" value="2.517" spread="0.3995"/>
                    <measurement group_id="O3" value="2.481" spread="0.4148"/>
                    <measurement group_id="O4" value="2.492" spread="0.3887"/>
                    <measurement group_id="O5" value="2.514" spread="0.4208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n = 104, 106, 102, 104, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.243" spread="0.6034"/>
                    <measurement group_id="O2" value="-0.200" spread="0.5940"/>
                    <measurement group_id="O3" value="-0.216" spread="0.6416"/>
                    <measurement group_id="O4" value="-0.308" spread="0.6630"/>
                    <measurement group_id="O5" value="-0.283" spread="0.6439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n = 104, 104, 102, 103, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.359" spread="0.7750"/>
                    <measurement group_id="O2" value="-0.362" spread="0.6883"/>
                    <measurement group_id="O3" value="-0.324" spread="0.7109"/>
                    <measurement group_id="O4" value="-0.369" spread="0.6679"/>
                    <measurement group_id="O5" value="-0.362" spread="0.6834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 104, 104, 101, 102, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.503" spread="0.7604"/>
                    <measurement group_id="O2" value="-0.439" spread="0.7179"/>
                    <measurement group_id="O3" value="-0.485" spread="0.7318"/>
                    <measurement group_id="O4" value="-0.510" spread="0.7924"/>
                    <measurement group_id="O5" value="-0.422" spread="0.7402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n = 104, 104, 101, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.426" spread="0.7881"/>
                    <measurement group_id="O2" value="-0.458" spread="0.7118"/>
                    <measurement group_id="O3" value="-0.465" spread="0.7365"/>
                    <measurement group_id="O4" value="-0.474" spread="0.7762"/>
                    <measurement group_id="O5" value="-0.392" spread="0.7236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n = 104, 104, 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.474" spread="0.7751"/>
                    <measurement group_id="O2" value="-0.612" spread="0.8283"/>
                    <measurement group_id="O3" value="-0.584" spread="0.7866"/>
                    <measurement group_id="O4" value="-0.474" spread="0.7525"/>
                    <measurement group_id="O5" value="-0.428" spread="0.7331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n = 104, 103, 100, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.541" spread="0.8543"/>
                    <measurement group_id="O2" value="-0.472" spread="0.8186"/>
                    <measurement group_id="O3" value="-0.594" spread="0.8256"/>
                    <measurement group_id="O4" value="-0.539" spread="0.7858"/>
                    <measurement group_id="O5" value="-0.438" spread="0.8296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Evening (p.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</title>
        <description>The evening reflective nasal congestion score was captured in participant diaries just before the 8;00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
        <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Evening (p.m.) Symptom Score for the Nasal Reflective Symptom Assessment by Study Day of the Treatment Period</title>
          <description>The evening reflective nasal congestion score was captured in participant diaries just before the 8;00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 109, 108, 106, 111, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.376" spread="0.4521"/>
                    <measurement group_id="O2" value="2.361" spread="0.4577"/>
                    <measurement group_id="O3" value="2.363" spread="0.4514"/>
                    <measurement group_id="O4" value="2.362" spread="0.4476"/>
                    <measurement group_id="O5" value="2.380" spread="0.4846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n = 102, 106, 101, 102, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.321" spread="0.6107"/>
                    <measurement group_id="O2" value="-0.285" spread="0.5961"/>
                    <measurement group_id="O3" value="-0.359" spread="0.7701"/>
                    <measurement group_id="O4" value="-0.321" spread="0.6852"/>
                    <measurement group_id="O5" value="-0.287" spread="0.7003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n = 102, 103, 102, 103, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.360" spread="0.7240"/>
                    <measurement group_id="O2" value="-0.410" spread="0.6650"/>
                    <measurement group_id="O3" value="-0.483" spread="0.8177"/>
                    <measurement group_id="O4" value="-0.466" spread="0.7646"/>
                    <measurement group_id="O5" value="-0.386" spread="0.7988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n = 104, 104, 101, 101, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.546" spread="0.7289"/>
                    <measurement group_id="O2" value="-0.512" spread="0.7049"/>
                    <measurement group_id="O3" value="-0.527" spread="0.8440"/>
                    <measurement group_id="O4" value="-0.480" spread="0.7346"/>
                    <measurement group_id="O5" value="-0.505" spread="0.7818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 104, 104, 101, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.536" spread="0.7524"/>
                    <measurement group_id="O2" value="-0.474" spread="0.7479"/>
                    <measurement group_id="O3" value="-0.597" spread="0.8653"/>
                    <measurement group_id="O4" value="-0.533" spread="0.8227"/>
                    <measurement group_id="O5" value="-0.450" spread="0.8142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n = 104, 102, 97, 99, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.526" spread="0.7398"/>
                    <measurement group_id="O2" value="-0.610" spread="0.7863"/>
                    <measurement group_id="O3" value="-0.564" spread="0.9052"/>
                    <measurement group_id="O4" value="-0.475" spread="0.7739"/>
                    <measurement group_id="O5" value="-0.485" spread="0.8870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n = 104, 103, 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.613" spread="0.8539"/>
                    <measurement group_id="O2" value="-0.750" spread="0.8105"/>
                    <measurement group_id="O3" value="-0.648" spread="0.8624"/>
                    <measurement group_id="O4" value="-0.597" spread="0.8704"/>
                    <measurement group_id="O5" value="-0.470" spread="0.8515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n = 104, 102, 100, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.613" spread="0.7920"/>
                    <measurement group_id="O2" value="-0.650" spread="0.7766"/>
                    <measurement group_id="O3" value="-0.588" spread="0.9323"/>
                    <measurement group_id="O4" value="-0.564" spread="0.7752"/>
                    <measurement group_id="O5" value="-0.520" spread="0.8781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period</title>
        <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
        <time_frame>Baseline and Day 2, 3, 4, 5, 6, and 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the a.m. Symptom Score for the Instantaneous Nasal Symptom Assessment by Study Day of the Treatment Period</title>
          <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 107, 106, 104, 106, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.271" spread="0.6669"/>
                    <measurement group_id="O2" value="2.311" spread="0.6527"/>
                    <measurement group_id="O3" value="2.298" spread="0.6809"/>
                    <measurement group_id="O4" value="2.311" spread="0.6228"/>
                    <measurement group_id="O5" value="2.406" spread="0.6030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n = 104, 105, 102, 103, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.147" spread="0.6807"/>
                    <measurement group_id="O2" value="0.010" spread="0.7568"/>
                    <measurement group_id="O3" value="-0.060" spread="0.7361"/>
                    <measurement group_id="O4" value="-0.010" spread="0.6308"/>
                    <measurement group_id="O5" value="-0.180" spread="0.7572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n = 104, 103, 102, 102, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.265" spread="0.9002"/>
                    <measurement group_id="O2" value="-0.206" spread="0.7491"/>
                    <measurement group_id="O3" value="-0.130" spread="0.8246"/>
                    <measurement group_id="O4" value="-0.112" spread="0.8234"/>
                    <measurement group_id="O5" value="-0.130" spread="0.7740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 104, 103,101,101, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.324" spread="0.8462"/>
                    <measurement group_id="O2" value="-0.255" spread="0.8288"/>
                    <measurement group_id="O3" value="-0.253" spread="0.9186"/>
                    <measurement group_id="O4" value="-0.351" spread="0.8421"/>
                    <measurement group_id="O5" value="-0.280" spread="0.8297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n = 104, 103, 101, 99, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.304" spread="0.7550"/>
                    <measurement group_id="O2" value="-0.314" spread="0.8672"/>
                    <measurement group_id="O3" value="-0.283" spread="0.8456"/>
                    <measurement group_id="O4" value="-0.232" spread="0.8927"/>
                    <measurement group_id="O5" value="-0.240" spread="0.6980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n = 104, 104, 100, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.353" spread="0.8402"/>
                    <measurement group_id="O2" value="-0.422" spread="0.9589"/>
                    <measurement group_id="O3" value="-0.337" spread="0.8961"/>
                    <measurement group_id="O4" value="-0.379" spread="0.8013"/>
                    <measurement group_id="O5" value="-0.260" spread="0.7333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n = 104, 102, 100, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.382" spread="0.8330"/>
                    <measurement group_id="O2" value="-0.376" spread="0.9258"/>
                    <measurement group_id="O3" value="-0.408" spread="0.9176"/>
                    <measurement group_id="O4" value="-0.404" spread="0.8591"/>
                    <measurement group_id="O5" value="-0.380" spread="0.7625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period</title>
        <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period.</description>
        <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline for the Daily Reflective Nasal Symptom Assessment Score by Study Day of the Treatment Period</title>
          <description>The reflective nasal congestion score was captured in participant diaries just before the 8:00 a.m. dose and 12 hours later just before the 8:00 p.m. dose. It is a composite score including four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The daily reflective nasal congestion symptom score was defined as the average of the morning and evening reflective nasal congestion score for the entire treatment period.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 109. 108, 106, 111, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.394" spread="0.3869"/>
                    <measurement group_id="O2" value="2.452" spread="0.3593"/>
                    <measurement group_id="O3" value="2.440" spread="0.3684"/>
                    <measurement group_id="O4" value="2.437" spread="0.3722"/>
                    <measurement group_id="O5" value="2.457" spread="0.4014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n = 102, 106, 101, 102, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.353" spread="0.5821"/>
                    <measurement group_id="O2" value="-0.367" spread="0.6130"/>
                    <measurement group_id="O3" value="-0.431" spread="0.7168"/>
                    <measurement group_id="O4" value="-0.389" spread="0.6408"/>
                    <measurement group_id="O5" value="-0.364" spread="0.6125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n = 104, 106, 102, 104, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.297" spread="0.5786"/>
                    <measurement group_id="O2" value="-0.320" spread="0.5181"/>
                    <measurement group_id="O3" value="-0.367" spread="0.5734"/>
                    <measurement group_id="O4" value="-0.392" spread="0.5406"/>
                    <measurement group_id="O5" value="-0.345" spread="0.6239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n = 104, 104, 102, 103, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.451" spread="0.6566"/>
                    <measurement group_id="O2" value="-0.449" spread="0.5989"/>
                    <measurement group_id="O3" value="-0.441" spread="0.6548"/>
                    <measurement group_id="O4" value="-0.425" spread="0.5806"/>
                    <measurement group_id="O5" value="-0.444" spread="0.6383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 104, 104, 101, 102, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.519" spread="0.6455"/>
                    <measurement group_id="O2" value="-0.468" spread="0.6256"/>
                    <measurement group_id="O3" value="-0.559" spread="0.6994"/>
                    <measurement group_id="O4" value="-0.520" spread="0.7017"/>
                    <measurement group_id="O5" value="-0.449" spread="0.6852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n = 104, 104, 101, 100, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.475" spread="0.6831"/>
                    <measurement group_id="O2" value="-0.550" spread="0.6478"/>
                    <measurement group_id="O3" value="-0.529" spread="0.7278"/>
                    <measurement group_id="O4" value="-0.484" spread="0.6992"/>
                    <measurement group_id="O5" value="-0.444" spread="0.6859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n = 104, 104, 100, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.543" spread="0.7267"/>
                    <measurement group_id="O2" value="-0.689" spread="0.7241"/>
                    <measurement group_id="O3" value="-0.635" spread="0.6890"/>
                    <measurement group_id="O4" value="-0.544" spread="0.7232"/>
                    <measurement group_id="O5" value="-0.460" spread="0.6943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n = 104, 103, 100, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.576" spread="0.7385"/>
                    <measurement group_id="O2" value="-0.573" spread="0.6821"/>
                    <measurement group_id="O3" value="-0.610" spread="0.7658"/>
                    <measurement group_id="O4" value="-0.556" spread="0.6695"/>
                    <measurement group_id="O5" value="-0.490" spread="0.7770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period</title>
        <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
        <time_frame>Baseline and Days 1, 2, 3, 4, 5, 6, and 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline for the Instantaneous Nasal Symptom Assessment Score By Study Day of the Treatment Period</title>
          <description>Instantaneous assessment of nasal symptoms was performed once daily before the
morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 107, 106, 104, 106, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.271" spread="0.6669"/>
                    <measurement group_id="O2" value="2.311" spread="0.6527"/>
                    <measurement group_id="O3" value="2.298" spread="0.6809"/>
                    <measurement group_id="O4" value="2.311" spread="0.6228"/>
                    <measurement group_id="O5" value="2.406" spread="0.6030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (n = 102, 104, 100, 99, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.147" spread="0.6807"/>
                    <measurement group_id="O2" value="0.010" spread="0.7568"/>
                    <measurement group_id="O3" value="-0.060" spread="0.7361"/>
                    <measurement group_id="O4" value="-0.010" spread="0.6308"/>
                    <measurement group_id="O5" value="-0.180" spread="0.7572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n = 102, 102, 100, 98, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.265" spread="0.9002"/>
                    <measurement group_id="O2" value="-0.206" spread="0.7491"/>
                    <measurement group_id="O3" value="-0.130" spread="0.8246"/>
                    <measurement group_id="O4" value="-0.112" spread="0.8234"/>
                    <measurement group_id="O5" value="-0.130" spread="0.7740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 102, 102, 99, 97, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.324" spread="0.8462"/>
                    <measurement group_id="O2" value="-0.255" spread="0.8288"/>
                    <measurement group_id="O3" value="-0.253" spread="0.9186"/>
                    <measurement group_id="O4" value="-0.351" spread="0.8421"/>
                    <measurement group_id="O5" value="-0.280" spread="0.8297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (n = 102, 102, 99, 95, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.304" spread="0.7550"/>
                    <measurement group_id="O2" value="-0.314" spread="0.8672"/>
                    <measurement group_id="O3" value="-0.283" spread="0.8456"/>
                    <measurement group_id="O4" value="-0.232" spread="0.8927"/>
                    <measurement group_id="O5" value="-0.240" spread="0.6980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (n =102, 102, 98, 95, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.353" spread="0.8402"/>
                    <measurement group_id="O2" value="-0.422" spread="0.9589"/>
                    <measurement group_id="O3" value="-0.337" spread="0.8961"/>
                    <measurement group_id="O4" value="-0.379" spread="0.8013"/>
                    <measurement group_id="O5" value="-0.260" spread="0.7333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n = 102, 101, 98, 94, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.382" spread="0.8330"/>
                    <measurement group_id="O2" value="-0.376" spread="0.9258"/>
                    <measurement group_id="O3" value="-0.408" spread="0.9176"/>
                    <measurement group_id="O4" value="-0.404" spread="0.8591"/>
                    <measurement group_id="O5" value="-0.380" spread="0.7625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximal Effect</title>
        <description>Time to maximal effect is defined as the earliest time that the nasal congestion symptom score demonstrates the greatest numerical difference from the placebo in change from baseline. The mean change from baseline scores for a treatment arm and for the placebo arm at each day and timepoint of the treatment period (Day 1 morn, Day 1 eve, etc) were calculated. Then the difference between the placebo and treatment arm means at each day/timepoint of the treatment period was calculated and recorded the day/timepoint that the difference between the treatment arm and the placebo was highest.</description>
        <time_frame>Baseline up to Day 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Effect</title>
          <description>Time to maximal effect is defined as the earliest time that the nasal congestion symptom score demonstrates the greatest numerical difference from the placebo in change from baseline. The mean change from baseline scores for a treatment arm and for the placebo arm at each day and timepoint of the treatment period (Day 1 morn, Day 1 eve, etc) were calculated. Then the difference between the placebo and treatment arm means at each day/timepoint of the treatment period was calculated and recorded the day/timepoint that the difference between the treatment arm and the placebo was highest.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7</title>
        <description>The magnitude of effect was measured as the change from baseline for the instantaneous nasal symptom assessment score at Day 7. Instantaneous assessment of nasal symptoms was performed once daily before the morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PE 10 mg</title>
            <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O2">
            <title>PE 20 mg</title>
            <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O3">
            <title>PE 30 mg</title>
            <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O4">
            <title>PE 40 mg</title>
            <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for the Instantaneous Nasal Symptom Assessment Score at Day 7</title>
          <description>The magnitude of effect was measured as the change from baseline for the instantaneous nasal symptom assessment score at Day 7. Instantaneous assessment of nasal symptoms was performed once daily before the morning dose. The instantaneous assessment was a composite score of four nasal symptoms: rhinorrhea, nasal congestion, nasal itching, and sneezing and is rated on a 0-3 scale of severity with 0 = absent symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms.</description>
          <population>The ITT population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.382" spread="0.8330"/>
                    <measurement group_id="O2" value="-0.376" spread="0.9258"/>
                    <measurement group_id="O3" value="-0.408" spread="0.9176"/>
                    <measurement group_id="O4" value="-0.404" spread="0.8591"/>
                    <measurement group_id="O5" value="-0.380" spread="0.7625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PE 10 mg</title>
          <description>PE 10 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="E2">
          <title>PE 20 mg</title>
          <description>PE 20 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="E3">
          <title>PE 30 mg</title>
          <description>PE 30 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="E4">
          <title>PE 40 mg</title>
          <description>PE 40 mg was administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Matching placebo tablets were administered orally every 4 hours in combination with background loratadine treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission or publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

